Genome Editing Technologies: Defining a Path to ClinicJacqueline Corrigan‐Curay, Matthew H. Porteus, Robert Jambou et al.|Molecular Therapy|2015Cited by 99
Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Cancer Research|2011Cited by 66
Supplementary References from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Unknown|2023Cited by 0
Supplementary Tables 1-5 from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Unknown|2023Cited by 0
Data from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010Hildegund C.J. Ertl, Scott E. Strome, John A. Zaia et al.|Unknown|2023Cited by 0